Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316602 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 632
- Enrollment target
NCT00316602 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 632 participants.
The verdict
NCT00316602, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 632 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
Interventions
- BIOLOGICAL IMVAMUNE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 632 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316602
The ClinicalTrials.gov registry entry for NCT00316602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 632 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMVAMUNE is the first listed.
NCT00316602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316602 about?
NCT00316602 is a clinical study titled "A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis". The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
What is the current status of trial NCT00316602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 632 participants. The study started on 2006-07. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00316602?
The interventions under investigation include: IMVAMUNE (BIOLOGICAL).
Who is sponsoring clinical trial NCT00316602?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.